30 research outputs found
Targeting monocyte chemotactic protein-1 synthesis with bindarit induces tumor regression in prostate and breast cancer animal models
n/
Associations between depressive symptoms and disease progression in older patients with chronic kidney disease: results of the EQUAL study
Background Depressive symptoms are associated with adverse clinical outcomes in patients with end-stage kidney disease; however, few small studies have examined this association in patients with earlier phases of chronic kidney disease (CKD). We studied associations between baseline depressive symptoms and clinical outcomes in older patients with advanced CKD and examined whether these associations differed depending on sex. Methods CKD patients (>= 65 years; estimated glomerular filtration rate <= 20 mL/min/1.73 m(2)) were included from a European multicentre prospective cohort between 2012 and 2019. Depressive symptoms were measured by the five-item Mental Health Inventory (cut-off <= 70; 0-100 scale). Cox proportional hazard analysis was used to study associations between depressive symptoms and time to dialysis initiation, all-cause mortality and these outcomes combined. A joint model was used to study the association between depressive symptoms and kidney function over time. Analyses were adjusted for potential baseline confounders. Results Overall kidney function decline in 1326 patients was -0.12 mL/min/1.73 m(2)/month. A total of 515 patients showed depressive symptoms. No significant association was found between depressive symptoms and kidney function over time (P = 0.08). Unlike women, men with depressive symptoms had an increased mortality rate compared with those without symptoms [adjusted hazard ratio 1.41 (95% confidence interval 1.03-1.93)]. Depressive symptoms were not significantly associated with a higher hazard of dialysis initiation, or with the combined outcome (i.e. dialysis initiation and all-cause mortality). Conclusions There was no significant association between depressive symptoms at baseline and decline in kidney function over time in older patients with advanced CKD. Depressive symptoms at baseline were associated with a higher mortality rate in men
Structure-Based Discovery of 1<i>H</i>‑Indazole-3-carboxamides as a Novel Structural Class of Human GSK‑3 Inhibitors
An
in silico screening procedure was performed to select new inhibitors
of glycogen synthase kinase 3β (GSK-3β), a serine/threonine
protein kinase that in the last two decades has emerged as a key target
in drug discovery, having been implicated in multiple cellular processes
and linked with the pathogenesis of several diseases. GSK-3β
inhibitors might prove useful as therapeutic compounds in the treatment
of conditions associated with elevated levels of enzyme activity,
such as type-2 diabetes and neurological disorders, for example, Alzheimer’s
disease, bipolar disorder, neuronal cell death, stroke, and depression.
In this work, virtual screening studies were applied to proprietary
compound libraries, and the functional activities of selected compounds
were assayed on human GSK-3β. The in silico screening procedure
enabled the identification of eight hit compounds showing pIC<sub>50</sub> values ranging from 4.9 to 5.5. X-ray crystallographic studies
resulted in a 2.50 Å three-dimensional structure of GSK-3β
complexed with one of the selected compounds, confirming that the
inhibitor interacts with the enzyme according to the docking hypothesis.
Importantly, molecular docking was able to find a new chemical scaffold
for GSK-3β inhibition, providing grounds for rational structure-based
design aimed at further optimization of the initial hits
α-Glyceryl-phosphoryl-ethanolamine protects human hippocampal neurons from ageing-induced cellular alterations
Brain ageing has been related to a decrease in cellular metabolism, to an accumulation of misfolded proteins and to an alteration of the lipid membrane composition. These alterations act as contributive aspects of age‐related memory decline by reducing membrane excitability and neurotransmitter release. In this sense, precursors of phospholipids (PLs) can restore the physiological composition of cellular membranes and ameliorate the cellular defects associated with brain ageing. In particular, phosphatidylcholine (PC) and phosphatidylethanolamine (PE) have been shown to restore mitochondrial function, reduce the accumulation of amyloid beta (Aβ) and, at the same time, provide the amount of acetylcholine needed to reduce memory deficit. Among PL precursors, alpha‐glycerylphosphorylethanolamine (GPE) has shown to protect astrocytes from Aβ injuries and to slow‐down ageing of human neural stem cells. GPE has been evaluated in aged human hippocampal neurons, which are implicated in learning and memory, and constitute a good in vitro model to investigate the beneficial properties of GPE. In order to mimic cellular ageing, the cells have been maintained 21 days in vitro and challenged with GPE. Results of the present paper showed GPE ability to increase PE and PC content, glucose uptake and the activity of the chain respiratory complex I and of the GSK‐3β pathway. Moreover, the nootropic compound showed an increase in the transcriptional/protein levels of neurotrophic and well‐being related genes. Finally, GPE counteracted the accumulation of ageing‐related misfolded proteins (a‐synuclein and tau). Overall, our data underline promising effects of GPE in counteracting cellular alterations related to brain ageing and cognitive decline
Effect of Sodium Hypochlorite 0.05% on MMP-9 Extracellular Release in Chronic Wounds
Background: In chronic wounds, high concentrations of matrix metalloproteinases (MMPs) can cause excessive proteolysis and slow wound healing. Consequently, restoring a proper MMP balance can help reduce the risk of a chronic wound. An antiseptic solution containing 0.05% sodium hypochlorite (Amukine Med 0.05%, Angelini S.p.A.; hereafter termed NaClO solution) is available on the market. The NaClO solution was proven effective and safe in managing infected skin wounds. To further characterize its activity, this study evaluated the in vitro activity of the NaClO solution on the monocyte release of MMPs. Methods: Human monocytic THP-1 (ATCC® TIB-202™) cell lines were differentiated into macrophages and treated with different concentrations of NaClO (from 0.05% to 5 × 10-7%). In addition, the THP-1 cell line was stimulated with wound fluid (WF) from patients with active venous leg ulcers in the inflammatory phase. The effect of NaClO (0.025-0.0062%) was also evaluated on healthy human peripheral blood serum samples. The effects of treatments on the gelatinolytic activity of MMP-9 were evaluated by gelatin zymography. The effects on MMPs release were evaluated through the Pro™ Human MMP 9-plex Assay. An exploratory scratch wound healing assay was also performed. Results: The NaClO solution reduced the gelatinolytic activity of MMP-9 and its activated form. The downregulation of MMP-9 gelatinolytic activity was also observed in peripheral blood serum. The MMPs profile showed a reduction in MMP-1 release (p < 0.05) and a slight reduction of the release of MMP-9 and MMP-12 after the treatment with LPS and the NaClO solution. A slight improvement in wound healing was observed after macrophage activation and treatment with the NaClO solution. Conclusions: The results obtained suggest a possible ability of the NaClO solution to modulate the proteolytic pathways in the wound microenvironment, further characterizing its activity and use in clinical practice during wound care
A specific combination of nutraceutical Ingredients exerts cytoprotective effects in human cholinergic neurons
Background: Brain aging is associated with an excessive reactive oxygen species (ROS) formation that causes cell injury through proteins oxidation and DNA damage. These changes have been identified as contributing factors in age-related memory decline. In this sense, treatments able to protect central nervous system (CNS) from oxidative stress and to sustain membrane plasticity, may represent new candidates to counter the development of aging effects. Several studies have indicated vitamin E, folic acid, magnesium and omega-3 as nutraceuticals protecting CNS from oxidative stress. Methods: A specific association of these active nutrients was tested in human cholinergic neurons, chosen as a cellular model related to learning and memory processes. Cortisol was used as an oxidative stress insult to explore the beneficial properties of the nutraceuticals. Results: In summary, the specific ratio of active ingredients in the above selected food supplement prevented the decrease in ATP content and in cell viability exerted by cortisol. At the same time, it prevented ROS formation, DNA damage, autophagy processes and decrease in the expression of cellular well-being genes induced by cell treatment with cortisol. The effects on ATP content, ROS formation and cellular viability were evidenced when the nutraceutical mix when administered following cortisol treatment, too. Notably, these peculiar evidences were significantly higher with respect to those elicited by the single components of the food supplement. Conclusions: Overall, these results confirm the beneficial effects of the simultaneous administration of vitamin E, folic acid, magnesium and omega-3
Antibacterial activity of novel dual bacterial DNA type II topoisomerase inhibitors.
In this study, a drug discovery programme that sought to identify novel dual bacterial topoisomerase II inhibitors (NBTIs) led to the selection of six optimized compounds. In enzymatic assays, the molecules showed equivalent dual-targeting activity against the DNA gyrase and topoisomerase IV enzymes of Staphylococcus aureus and Escherichia coli. Consistently, the compounds demonstrated potent activity in susceptibility tests against various Gram-positive and Gram-negative reference species, including ciprofloxacin-resistant strains. The activity of the compounds against clinical multidrug-resistant isolates of S. aureus, Clostridium difficile, Acinetobacter baumannii, Neisseria gonorrhoeae, E. coli and vancomycin-resistant Enterococcus spp. was also confirmed. Two compounds (1 and 2) were tested in time-kill and post-antibiotic effect (PAE) assays. Compound 1 was bactericidal against all tested reference strains and showed higher activity than ciprofloxacin, and compound 2 showed a prolonged PAE, even against the ciprofloxacin-resistant S. aureus BAA-1720 strain. Spontaneous development of resistance to both compounds was selected for in S. aureus at frequencies comparable to those obtained for quinolones and other NBTIs. S. aureus BAA-1720 mutants resistant to compounds 1 and 2 had single point mutations in gyrA or gyrB outside of the quinolone resistance-determining region (QRDR), confirming the distinct site of action of these NBTIs compared to that of quinolones. Overall, the very good antibacterial activity of the compounds and their optimizable in vitro safety and physicochemical profile may have relevant implications for the development of new broad-spectrum antibiotics